Eisai, Biogen Present Long-Term Leqembi Data Showing Sustained Alzheimer's Benefits
Eisai (4523.T) and Biogen (BIIB) presented long-term data from the Clarity AD trial, showing sustained benefits of Leqembi (lecanemab) in early Alzheimer's patients. Continuous treatment reduced disease progression risk by 36% and 49% compared to ADNI data. Leqembi is approved in 53 countries, with global sales of 32.2 billion yen in Q3.
How this was made
The 30-second read
Why it matters
Five-year durability claims (progression risk reductions vs ADNI, and no new safety findings) can strengthen the perceived clinical credibility of Leqembi, supporting investor sentiment and potentially influencing expectations for continued uptake and future label discussions.
Market read
Traders may view the long-term efficacy durability and unchanged safety profile as incremental positive information for the Leqembi franchise, though it is not a new regulatory decision.
What to watch
No new safety findings are reassuring, but the piece does not quantify adverse event rates, discontinuations, or subgroup effects, which may limit how far the market reprices near-term sales expectations.
Background
The article reports long-term Phase 3 Clarity AD (placebo-controlled core with LTE) data presented at CTAD, focusing on progression to next disease stage and safety over up to five years.
Ticker impact
Biogen presented Phase 3 Clarity AD long-term data showing continuous lecanemab treatment sustained benefits and no new safety findings over five years.
Likely modest upward bias as investors price in durability of Leqembi’s clinical benefit and reduced perceived tail-risk.
The article highlights five-year progression outcomes and states no new safety signals, which can strengthen confidence in ongoing commercialization and future regulatory/label discussions.
Market effects
Reinforces confidence in Alzheimer’s anti-amyloid monoclonal antibody class durability, potentially supporting sentiment toward other neurodegeneration developers.
Could modestly lift Japan biotech sentiment via Eisai’s foreign-exchange listing narrative, but primary impact is on Alzheimer’s-focused investors.
International clinical durability data can influence global payer and clinician expectations, affecting broader demand outlook for anti-amyloid therapies.
Counterpoint
The article compares lecanemab outcomes to ADNI rather than a randomized long-term control, so investors may discount the magnitude of relative benefit.
Key entities
- companyEisai Co., Ltd.
Presented CTAD long-term Clarity AD data for lecanemab (Leqembi), including five-year progression outcomes and safety commentary.
- companyBiogen Inc.
Co-presented CTAD long-term Clarity AD data for lecanemab, highlighting sustained benefits and no new safety findings over five years.
- productLeqembi (lecanemab-irmb)
Anti-amyloid monoclonal antibody for early Alzheimer’s disease; the article focuses on sustained efficacy and safety over up to five years.
- clinical_trialClarity AD trial
Phase 3 placebo-controlled study with long-term extension; the article reports LTE results up to five years.



